{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:03:54Z","timestamp":1772017434456,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00417-021-05324-8","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T02:02:20Z","timestamp":1627005740000},"page":"3649-3654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment contentment and preference of patients undergoing intravitreal anti-VEGF therapy"],"prefix":"10.1007","volume":"259","author":[{"given":"Ulrich","family":"Kellner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Seleman","family":"Bedar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Weinitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazaleh","family":"Farmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebru Nida","family":"S\u00fcr\u00fcl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Maria","family":"Weide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Schick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"5324_CR1","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.ophtha.2020.01.029","volume":"127","author":"C Writing","year":"2020","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research G, Writing C, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd (2020) Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 127:S135\u2013S145. https:\/\/doi.org\/10.1016\/j.ophtha.2020.01.029","journal-title":"Ophthalmology"},{"key":"5324_CR2","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","volume":"118","author":"DM Brown","year":"2011","unstructured":"Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N, Adamis AP, Rubio RG, Murahashi WY (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594\u20131602. https:\/\/doi.org\/10.1016\/j.ophtha.2011.02.022","journal-title":"Ophthalmology"},{"key":"5324_CR3","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","volume":"118","author":"PA Campochiaro","year":"2011","unstructured":"Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041\u20132049. https:\/\/doi.org\/10.1016\/j.ophtha.2011.02.038","journal-title":"Ophthalmology"},{"key":"5324_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, Rise, Group RR (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039","journal-title":"Ophthalmology"},{"key":"5324_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317434","author":"V Daien","year":"2020","unstructured":"Daien V, Finger RP, Talks JS, Mitchell P, Wong TY, Sakamoto T, Eldem BM, Korobelnik JF (2020) Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317434","journal-title":"Br J Ophthalmol"},{"key":"5324_CR6","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00417-016-3384-0","volume":"254","author":"H Senra","year":"2016","unstructured":"Senra H, Ali Z, Balaskas K, Aslam T (2016) Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefes Arch Clin Exp Ophthalmol 254:1873\u20131880. https:\/\/doi.org\/10.1007\/s00417-016-3384-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"5324_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0264619613481778","volume":"31","author":"C Thetford","year":"2013","unstructured":"Thetford C, Hodge S, Harding S, Taylor S, Knox PC (2013) Living with age-related macular degeneration treatment: patient experiences of being treated with ranibizumab (Lucentis) intravitreal injections. Br J Vis Impair 31(2):89\u2013101. https:\/\/doi.org\/10.1177\/0264619613481778","journal-title":"Br J Vis Impair"},{"key":"5324_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2017.03.005","volume":"177","author":"H Senra","year":"2017","unstructured":"Senra H, Balaskas K, Mahmoodi N, Aslam T (2017) Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol 177:213\u2013224. https:\/\/doi.org\/10.1016\/j.ajo.2017.03.005","journal-title":"Am J Ophthalmol"},{"key":"5324_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.4103\/ijo.IJO_1269_20","volume":"69","author":"S Mekala","year":"2021","unstructured":"Mekala S, Dhoble P, Vishwaraj CR, Khodifad AM, Hess OM, Lavanya GS (2021) Subjective and objective measures of the patient experience before, during, and after intravitreal anti-vascular endothelial growth factor injections. Indian J Ophthalmol 69:890\u2013894. https:\/\/doi.org\/10.4103\/ijo.IJO_1269_20","journal-title":"Indian J Ophthalmol"},{"key":"5324_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jfo.2014.11.015","volume":"38","author":"E Boulanger-Scemama","year":"2015","unstructured":"Boulanger-Scemama E, Querques G, About F, Puche N, Srour M, Mane V, Massamba N, Canoui-Poitrine F, Souied EH (2015) Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol 38:620\u2013627. https:\/\/doi.org\/10.1016\/j.jfo.2014.11.015","journal-title":"J Fr Ophtalmol"},{"key":"5324_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12886-020-01397-x","volume":"20","author":"I Volkmann","year":"2020","unstructured":"Volkmann I, Knoll K, Wiezorrek M, Greb O, Framme C (2020) Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients\u2019 persistence. BMC Ophthalmol 20:122. https:\/\/doi.org\/10.1186\/s12886-020-01397-x","journal-title":"BMC Ophthalmol"},{"key":"5324_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-013-2412-6","volume":"252","author":"KM Droege","year":"2014","unstructured":"Droege KM, Caramoy A, Kersten A, Luberichs-Fauser J, Zilkens K, Muller D, Kirchhof B, Fauser S (2014) Patient preference of ranibizumab treatment regimen for neovascular age-related macular degeneration - monthly injections versus pro re nata. Graefes Arch Clin Exp Ophthalmol 252:31\u201334. https:\/\/doi.org\/10.1007\/s00417-013-2412-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5324_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ophtha.2015.12.001","volume":"123","author":"S Mueller","year":"2016","unstructured":"Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T (2016) Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology 123:876\u2013883. https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.001","journal-title":"Ophthalmology"},{"key":"5324_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/PPA.S228890","volume":"14","author":"T Joko","year":"2020","unstructured":"Joko T, Nagai Y, Mori R, Tanaka K, Oshima Y, Hikichi Y, Komori T, Carrasco J, Maculaitis MC, Will O, Beusterien K, Takahashi K (2020) Patient preferences for anti-vascular endothelial growth factor treatment for wet age-related macular degeneration in Japan: a discrete choice experiment. Patient Prefer Adherence 14:553\u2013567. https:\/\/doi.org\/10.2147\/PPA.S228890","journal-title":"Patient Prefer Adherence"},{"key":"5324_CR15","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","volume":"20","author":"RP Finger","year":"2020","unstructured":"Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Sakamoto T, Wong TY, Pantiri K, Carrasco J (2020) Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol 20:294. https:\/\/doi.org\/10.1186\/s12886-020-01554-2","journal-title":"BMC Ophthalmol"},{"key":"5324_CR16","doi-asserted-by":"publisher","first-page":"CD009510","DOI":"10.1002\/14651858.CD009510.pub3","volume":"7","author":"Z Shalchi","year":"2020","unstructured":"Shalchi Z, Mahroo O, Bunce C, Mitry D (2020) Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 7:CD009510. https:\/\/doi.org\/10.1002\/14651858.CD009510.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"5324_CR17","doi-asserted-by":"publisher","first-page":"CD007419","DOI":"10.1002\/14651858.CD007419.pub5","volume":"6","author":"G Virgili","year":"2017","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E (2017) Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev 6:CD007419. https:\/\/doi.org\/10.1002\/14651858.CD007419.pub5","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05324-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05324-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05324-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:47:27Z","timestamp":1744188447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05324-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5324"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05324-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"5 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The questioning was performed anonymously during the regular quality assessment of medical care in a large outpatient ophthalmologic tertiary centre. Anonymous data collection and analysis do not require ethical permission of the local ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Prior to answering the questionnaire, patients were informed that their responses were analysed anonymously and with\u00a0responding to the\u00a0questionnaire they would agree to this\u00a0data evaluation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have given their approval for this version to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"T Schick has received speaker honoraria from Bayer and Novartis and has served on an advisory board for Allergan. The other authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}